Compounds > st 1535
Page last updated: 2024-08-02 10:04:23

st 1535

Description

Cross-References

ID SourceID
PubMed CID9860294
CHEMBL ID197669
SCHEMBL ID5362208
MeSH IDM0493042

Synonyms (22)

Synonym
2-butyl-9-methyl-8-(triazol-2-yl)purin-6-amine
st-1535 ,
L001675
CHEMBL197669 ,
st1535
2-butyl-9-methyl-8-(2h-1,2,3-triazol-2-yl)-9h-purin-6-amine
2-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9h-purin-6-ylamine
bdbm50176058
st 1535
496955-42-1
gtpl5613
SCHEMBL5362208
DTXSID60432000
2-butyl-9-methyl-8-(2h-1,2,3-triazol-2-yl)-9h-purin-6-ylamine
AKOS030562134
AS-35290
Q27088881
SB16783
A913876
BS165703
ct-1500
NTK8WWM73W

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Adenosine receptor A3Homo sapiens (human)Ki5.5000AID1138025; AID254515
Adenosine receptor A2aHomo sapiens (human)IC500.4300AID756878
Adenosine receptor A2aHomo sapiens (human)Ki0.0074AID1138023; AID254542; AID365580; AID747271; AID756879
Adenosine receptor A2bHomo sapiens (human)Ki0.3521AID1138021; AID254541
Adenosine receptor A1Homo sapiens (human)Ki0.0807AID1138024; AID254536; AID747272; AID756877
Delta-type opioid receptorMus musculus (house mouse)Ki0.0066AID365580
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.0066AID365580

Bioassays (60)

Assay IDTitleYearJournalArticle
AID255282Percent inhibition against Acetylcholine transporter at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID756877Displacement of [3H]DPCPX from human recombinant adenosine A1 receptor expressed in CHO-K1 cells after 60 mins2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
ISSN: 1520-4804		Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease.
AID255262Percent inhibition against GABA transporter at a compound concentration of 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255257Percent inhibition against NMDA receptor at a compound concentration of 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255274Percent inhibition against Dopamine receptor D2 at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255288Percent inhibition against ADO transporter at 1 uM nonselective2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255298Percent inhibition against Muscarinic acetylcholine receptor M5 at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255270Percent inhibition against GABA-B receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID254536Binding affinity towards human Adenosine A1 receptor expressed in CHO cells using 1 nM [3H]DPCPX2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255284Percent inhibition against Beta-1 adrenergic receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1138036Selectivity ratio of Ki for human recombinant adenosine receptor A2b to Ki for human recombinant adenosine receptor A2a2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
ISSN: 1520-4804		Adenosine A2A receptor as a drug discovery target.
AID747271Antagonist activity at human adenosine A2A receptor assessed as cAMP level by cell based assay2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
ISSN: 1464-3405		Novel adenosine A(2A) receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A(2A) receptor antagonists for extending into extracellular space.
AID255315Percent inhibition against 5-hydroxytryptamine 2C receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1138021Inhibition of human recombinant adenosine receptor A2b2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
ISSN: 1520-4804		Adenosine A2A receptor as a drug discovery target.
AID255256Percent inhibition against AMPA receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255268Percent inhibition against P2Y Purinoceptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255297Percent inhibition against Muscarinic acetylcholine receptor M4 at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID756879Displacement of [3H]ZM241385 from human recombinant adenosine A2A receptor expressed in HEK293 cells after 1 hr by competitive binding assay2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
ISSN: 1520-4804		Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease.
AID747272Antagonist activity at human adenosine A1 receptor assessed as cAMP level by cell based assay2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
ISSN: 1464-3405		Novel adenosine A(2A) receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A(2A) receptor antagonists for extending into extracellular space.
AID365580Binding affinity to human adenosine A2A receptor2008Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
ISSN: 1520-4804		2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists.
AID255287Percent inhibition against Alpha-2 adrenergic receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255254Percent inhibition against PCP receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255317Percent inhibition against 5-hydroxytryptamine transporter at 1 uM nonselective2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255295Percent inhibition against Muscarinic acetylcholine receptor M2 at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1138020Selectivity ratio of Ki for human recombinant adenosine A1 receptor to Ki for human recombinant adenosine receptor A2a2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
ISSN: 1520-4804		Adenosine A2A receptor as a drug discovery target.
AID255313Percent inhibition against 5-hydroxytryptamine 1A receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID756878Antagonist activity at human adenosine A2A receptor expressed in HEK293 cells assessed as inhibition of NECA-induced cAMP accumulation incubated for 10 mins prior to NECA addition2013Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13
ISSN: 1520-4804		Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease.
AID255277Percent inhibition against Dopamine receptor D5 at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255285Percent inhibition against Beta-2 adrenergic receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255286Percent inhibition against Alpha-1 adrenergic receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255314Percent inhibition against 5-hydroxytryptamine 2A receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255303Percent inhibition against Norepinephrine transporter at 1 uM nonselective2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID254541Binding affinity towards human Adenosine A2b receptor expressed in HEK293 cells using 5 nM [3H]DPCPX2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255310Percent inhibition against 5-hydroxytryptamine 3 receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1138024Inhibition of human recombinant adenosine A1 receptor2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
ISSN: 1520-4804		Adenosine A2A receptor as a drug discovery target.
AID255281Percent inhibition against P2X Purinergic receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID254515Binding affinity towards human Adenosine A3 receptor expressed in HEK293 cells using 0.1 nM [3H]AB-MECA2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255292Percent inhibition against Dopamine transporter at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255312Percent inhibition against 5-hydroxytryptamine 6 receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255279Percent inhibition against Histamine H1 receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255267Percent inhibition against Kainate receptor at a compound concentration of 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1138023Inhibition of human recombinant adenosine receptor A2a2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
ISSN: 1520-4804		Adenosine A2A receptor as a drug discovery target.
AID255296Percent inhibition against Muscarinic acetylcholine receptor M3 at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255316Percent inhibition against 5-hydroxytryptamine 5A receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255311Percent inhibition against 5-hydroxytryptamine 4 receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255275Percent inhibition against Dopamine receptor D3 at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255309Percent inhibition against Opioid receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255294Percent inhibition against Muscarinic acetylcholine receptor M1 at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255280Percent inhibition against central Benzodiazepine receptor at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID254542Binding affinity towards human Adenosine A2a receptor expressed in HEK293 cells using 6 nM [3H]CGS-216802005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255276Percent inhibition against Dopamine receptor D4 at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1138025Inhibition of human recombinant adenosine A3 receptor2014Journal of medicinal chemistry, May-08, Volume: 57, Issue:9
ISSN: 1520-4804		Adenosine A2A receptor as a drug discovery target.
AID255370Selective binding affinity towards human Adenosine A1 receptor expressed in CHO cells using [3H]DPCPX compared to human Adenosine A2a receptor expressed in HEK293 cells using [3H]-CGS-21,6802005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255273Percent inhibition against Dopamine receptor D1 at 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255278Percent inhibition against GABAA receptor alpha at a compound concentration of 1 uM2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID255371Selective binding affinity towards human Adenosine A2b receptor expressed in HEK293 cells using [3H]-DPCPX compared to human Adenosine A2a receptor expressed in HEK293 cells using [3H]CGS-216802005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1345721Human A2B receptor (Adenosine receptors)2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1345822Human A3 receptor (Adenosine receptors)2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1345618Human A2A receptor (Adenosine receptors)2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
AID1345685Human A1 receptor (Adenosine receptors)2005Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22
ISSN: 0022-2623		2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
8-hydroxy-2-(di-n-propylamino)tetralin
1
phenols;
tertiary amino compound;
tetralins		serotonergic antagonist2005200519.0low000100
1,3-dipropyl-8-cyclopentylxanthine
2
oxopurineadenosine A1 receptor antagonist;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor		2005200817.5low000200
theophylline
1
dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent		2014201410.0low000010
atenolol
1
ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic		2005200519.0low000100
baclofen
1
amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant		2005200519.0low000100
caffeine
2
purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic		2013201410.5low000020
cgs 15943
2
aromatic amine;
biaryl;
furans;
organochlorine compound;
primary amino compound;
quinazolines;
triazoloquinazoline		adenosine A1 receptor antagonist;
adenosine A2A receptor antagonist;
antineoplastic agent;
central nervous system stimulant		2008201413.0low000110
diazepam
1
1,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic		2005200519.0low000100
ici 118551
1
indanes2005200519.0low000100
imipramine
1
dibenzoazepineadrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor		2005200519.0low000100
ketanserin
1
aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist		2005200519.0low000100
methoctramine
1
aromatic ether;
tetramine		muscarinic antagonist2005200519.0low000100
muscimol
1
alkaloid;
isoxazoles;
primary amino compound		fungal metabolite;
GABA agonist;
oneirogen;
psychotropic drug		2005200519.0low000100
nipecotic acid
1
beta-amino acid;
piperidinemonocarboxylic acid		2005200519.0low000100
pirenzepine
1
pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist		2005200519.0low000100
prazosin
1
aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor		2005200519.0low000100
protriptyline
1
carbotricyclic compoundantidepressant2005200519.0low000100
pyrilamine
1
aromatic ether;
ethylenediamine derivative		H1-receptor antagonist2005200519.0low000100
8-(4-((2-aminoethyl)aminocarbonylmethyloxy)phenyl)-1,3-dipropylxanthine
1
2013201311.0low000010
yohimbine
1
methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist		2005200519.0low000100
2-chloroadenosine
1
purine nucleoside2014201410.0low000010
hemicholinium 3
1
2005200519.0low000100
kainic acid
1
dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist		2005200519.0low000100
glutamic acid
1
glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical		2005200519.0low000100
butaclamol
1
amino alcohol;
organic heteropentacyclic compound;
tertiary alcohol;
tertiary amino compound		dopaminergic antagonist2005200519.0low000100
adenosine
1
adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent		2014201410.0low000010
4-nitrobenzylthioinosine
1
purine nucleoside2005200519.0low000100
selfotel
1
non-proteinogenic alpha-amino acid2005200519.0low000100
mesulergine
1
ergot alkaloid;
sulfamides		antiparkinson drug;
dopamine agonist;
serotonergic antagonist		2005200519.0low000100
alpha,beta-methyleneadenosine 5'-triphosphate
1
nucleoside triphosphate analogue2005200519.0low000100
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
1
adenosines;
monocarboxylic acid amide;
organoiodine compound		adenosine A3 receptor agonist2005200519.0low000100
zm 241385
4
diamino-1,3,5-triazine2005201414.0low000220
sch 58261
2
triazolopyrimidines2008201413.0low000110
dizocilpine
1
secondary amino compound;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist		2005200519.0low000100
2'-deoxyadenosine 5'-o-(1-thiotriphosphate)
1
2005200519.0low000100
regadenoson
1
purine nucleoside2014201410.0low000010
adenosine-5'-(n-ethylcarboxamide)
2
adenosines;
monocarboxylic acid amide		adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent		2008201413.0low000110
wr-142,490
1
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanolantimalarial2014201410.0medium000010
n(6)-cyclopentyladenosine
1
2008200816.0low000100
bemesetron
1
2005200519.0low000100
4-diphenylacetoxy-n-methylpiperidine methiodide
1
iodide salt;
quaternary ammonium salt		cholinergic antagonist;
muscarinic antagonist		2005200519.0low000100
sch 23390
1
benzazepine2005200519.0low000100
2-((2-aminoethylamino)carbonylethylphenylethylamino)-5'-n-ethylcarboxamidoadenosine
1
2014201410.0low000010
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine
1
adenosines;
dicarboxylic acid monoamide;
monocarboxylic acid		adenosine A2A receptor agonist;
anti-inflammatory agent		2014201410.0low000010
naloxone
1
morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist		2005200519.0low000100
istradefylline
3
oxopurine2005201413.3low000120
isoalloxazine
1
benzo[g]pteridine-2,4-dione2005200519.0low000100
cv 1808
1
purine nucleoside2014201410.0low000010
binodenoson
1
2014201410.0low000010
atl 146e
1
2014201410.0low000010
2-(2-(4-chlorophenyl)ethoxy)adenosine
1
2014201410.0medium000010
2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7h-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine
1
2014201410.0low000010
tozadenant
1
benzothiazoles2014201410.0low000010
v 2006
1
2014201410.0medium000010
clozapine
1
benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound		adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic		2005200519.0low000100
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Idiopathic Parkinson Disease0
1
2013201311.0high000010
Parkinson Disease0
1
2013201311.0high000010